Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01722487 · OUTCOME

Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL · Source last updated 2017-11-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
Not reported
Time frame
Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.

What was measured

In randomized subjects with baseline platelet ≤ 100 x 10\^9/L, the proportion of subjects who achieved platelet \>100 x 10\^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors.

Analysis population: Subjects With Baseline Thrombocytopenia

Groups in this outcome

Ibrutinib

Ibrutinib 420 mg daily.

Chlorambucil

Chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) days 1 and 15 of 28-day cycle up to 12 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ibrutinib35
Chlorambucil28

Reported measurements

Source class 1
Values in Percentage of Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ibrutinib77.1Not reportedNot reportedNot reportedNot reported
Chlorambucil42.9Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    .0054
    statistical Method
    Chi-squared
Complete source fields
analyses
  1. group Ids
    1. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    .0054
    statistical Method
    Chi-squared
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        77.1
      2. group Id
        OG001
        value
        42.9
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    2. group Id
      OG001
      value
      28
    units
    Participants
description
In randomized subjects with baseline platelet ≤ 100 x 10\^9/L, the proportion of subjects who achieved platelet \>100 x 10\^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors.
groups
  1. description
    Ibrutinib 420 mg daily.
    id
    OG000
    title
    Ibrutinib
  2. description
    Chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) days 1 and 15 of 28-day cycle up to 12 cycles
    id
    OG001
    title
    Chlorambucil
param Type
NUMBER
population Description
Subjects With Baseline Thrombocytopenia
reporting Status
POSTED
time Frame
Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.
title
Proportion of Sustained Platelet Improvement in Subjects With Baseline Thrombocytopenia
type
SECONDARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice